SEC Form 4 · accession 0001209191-18-025732
NovoCure Ltd · NVCR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Eilon D. Kirson
Officer — Chief Science Officer
Period of report
Apr 18, 2018
Accepted (ET)
Apr 20, 2018 · 4:53 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001645113
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary SharesF1 | Apr 18, 2018 | M | 76,869 | $3.44 | A | 116,451 | D | |
| Ordinary SharesF1 | Apr 18, 2018 | S | 76,869 | $24.00 | D | 39,582 | D | |
| Ordinary SharesF1 | Apr 18, 2018 | M | 70,956 | $3.44 | A | 110,538 | D | |
| Ordinary SharesF1 | Apr 18, 2018 | S | 70,956 | $24.00 | D | 39,582 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Options to Buy Ordinary SharesF2 | $3.44 | Apr 18, 2018 | M | 76,869 | A | Sep 14, 2021 | — | Ordinary Shares | 76,869 | 0 | D |
| Options to Buy Ordinary SharesF2 | $3.44 | Apr 18, 2018 | M | 70,956 | A | Dec 31, 2021 | — | Ordinary Shares | 70,956 | 0 | D |
Explanation of responses
- F1These shares were sold pursuant to a Rule 10b5-1 trading plan adopted by Mr. Kirson.
- F2Fully vested as of the date hereof.